식물 발현 벡터에 EPO, BMP, TPA, BGH 등의 의료용 단백질 유전자를 클로닝하여 담배와 이끼 등 식물체에 형질전환하여 그 발현 정도와 기내 활성도를 관찰하였다. 유전자 도입에 따른 식물 형태적 특성의 변화를 관찰하였으며, 이끼 유용 단백질인 physcomitrin을 2-D 기법으로 확인하였고 hemolytic 특성과 스트레스 관련성을 규명하였다.
In this project, we cloned the useful genes coding pharmaceutical proteins, transformed those cloned genes into tobacco and a moss, Physcomitrella patens, and characterized their expression in those overexpressed lines and their morphological alterations affected by the overexpression of the introdu
In this project, we cloned the useful genes coding pharmaceutical proteins, transformed those cloned genes into tobacco and a moss, Physcomitrella patens, and characterized their expression in those overexpressed lines and their morphological alterations affected by the overexpression of the introduced gene. Using the previously established mass culture system for the moss, we isolated the proteins expressed by those plants, and characterized the in vitro activity of recombinant proteins. For these purposes, we used erythropoietin (EPO), tissue-type plasminogen activator (TPA), bone morphogenetic protein (BMP), bovine growth hormone (BGH), and major histocompatibility complex I (MHC I) genes. The presense of introduced genes were identified by genomic PCR and Southern analysis. Foreign gene expression within transgenic plants were examined by Northern analyses or RT-PCR. Several morphological alterations were observed in those overexpressed lines of tobacco and the moss. We also could isolated a cytolytic protein, physcomitrin, by the 2-D proteomic study, and identified its hemolytic activity and biotic and abiotic defense-related effect. Four articles were published in the international journals, and five domestic patents were registered. Recently, plant biotechnology combined with plant tissue culture techniques has been rapidly developed to engineer crop plants. Furthermore, plants are very attractive biological systems for the production of pharmaceutical recombinant proteins owing to many advantages, such as mass production with relatively low costs, extremely stable storage of proteins in tissues, similarity of translational modification machinery with animal, and safety from animal virus contamination. Therefore, it is worthy of trying to produce pharmaceutical proteins through nuclear and plastid transformation in mass scale with a view of industrialization. Transgenic plants from this project will be distributed to other institutes for further application. In addition, P. patens is going to be supplied as a model plant system and a bioreactor for the production of pharmaceuticals.